source
- Roche reports positive interim Phase 3 results for kidney drug, paving way for accelerated approvalRoche announced interim results from its Phase 3 trial of a kidney disease therapy, indicating the study met its primary endpoints. The data, released on Wednesday, suggest the drug could qualify…
- Boehringer Ingelheim boosts Variant Bio partnership with $250 million for cardiovascular researchBoehringer Ingelheim announced an expansion of its collaboration with Variant Bio. The partnership will now include cardiovascular disease research, broadening its original scope. The deal value…